Tumour necrosis factor inhibitors: maximizing patient safety.
Cairns
A P
AP
Taggart
A J
AJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007239:Infections / Q000209:etiology*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D017751:Safety Management; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept